GCM
ENTA icon

Graham Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Graham Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37,323
Closed -$447K – 1322
2025
Q3 		$447K Buy
37,323
+18,593
+99% +$149K 0.01% 660
2025
Q2 		$142K Sell
18,730
-1,292
-6% -$7.77K ﹤0.01% 1175
2025
Q1 		$111K Buy
+20,022
New +$124K ﹤0.01% 1203
2024
Q1 		– Sell
-13,360
Closed -$126K – 1133
2023
Q4 		$126K Buy
+13,360
New +$124K ﹤0.01% 896

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Graham Capital Management's ENTA Position: Q4 2025 in Review

Graham Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 37,323 shares — an estimated $447K sold.

Graham Capital Management first reported a position in ENTA in Q4 2023 and held it in 4 quarters. The position peaked at $447K in Q3 2025. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • Graham Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 37,323 Enanta Pharmaceuticals shares in Q4 2025, an estimated $447K.
  • Graham Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Graham Capital Management's Enanta Pharmaceuticals position peaked at $447K in Q3 2025.
  • 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.